S'abonner

Protective effect of Xin-Ji-Er-Kang on cardiovascular remodeling in high-salt induced hypertensive mice: Role ofoxidative stress and endothelial dysfunction - 09/06/19

Doi : 10.1016/j.biopha.2019.108937 
Xiao-yun Wang a, 1, Guang-yao Huang a, 1, Feng-zhen Lian a, 1, Ming Pan a, 1, Cheng-shao Ruan a, Xin-xin Ling a, Mei-ling Chen b, Ai-zong Shen c, , Shan Gao a,
a Department of Pharmacology, Basic Medical College, Anhui Medical University, Hefei 230032, PR China 
b Cancer Hospital, Chinese Academy of Sciences,Hefei 230032, PR China 
c The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, PR China 

Corresponding authors.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages 11
Iconographies 9
Vidéos 0
Autres 0

Highlights

A high-salt diet induces hypertension, which eventually leads to cardiovascular remodeling.
High-salt induced hypertensive mice have obvious oxidative stress and endothelial dysfunction.
As a prescription that has been used in clinical practice for many years,Xin-Ji-Er-Kanghas the function of antioxidant and balance endothelin system.
XJEK mitigates cardiac remodeling in high-salt-induced hypertensive mice.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

Xin-Ji-Er-Kang (XJEK) is a Chinese herbal formula that has beenreported to exert effective protection against cardiovascular diseases, such as hypertension and myocarditis.

Objective

The aim of the present study was to investigate the effect of XJEK on high-salt-induced hypertensive mice and its possible mechanism.

Methods

The model of hypertension was established through a high-salt diet. Sixty male Kunming mice were randomized into six groups, namely the Control, Model, Low-dose XJEK, Middle-dose XJEK, High-dose XJEK and Fosinopril groups (n=10 per group). Different steady interventions were given to each group: 0.9% Sodium chloride was added to the diet of the Control group and 8% sodium chloride to the diet of the other five groups from the very beginning. An additional 4, 8 and 12 g/kg/day XJEK were intragastrically administered to the Low-dose, Middle-dose and High-dose XJEK groups, respectively, and 2 mg/kg/day fosinopril to the fosinopril group, from the start of week 5. Systolic blood pressure (SBP) was measured weekly from weeks 1 to 8 using the tail-cuff method. At the end of week 8, left ventricular (LV) systolic pressure, LV end-diastolic pressure and rate of rise of LV pressure were examined using a TransonicScisense catheter (Transonic Systems Inc,Ithaca, NY,USA). Endothelium-dependent relaxations induced by acetylcholine were observed in an isolated thoracic aorta ring. Serum and heartsweresampled for the measurement of the following indexes:Serum nitric oxide (NO), superoxide dismutase (SOD) activity and malondialdehyde (MDA) content (determined by colorimetricanalysis); serum angiotensin II(Ang II), endothelin-1, endothelial NO synthase (eNOS), asymmetric dimethylarginine (ADMA), tetrahydrobiopterin (BH4) concentration and l-arginine (determined by enzyme-linked immunosorbent assay); heart to body weight (HW/BW) ratio; myocardial morphological change (determined by HE and VG staining); myocardial eNOS expression (determined by immunofluorescence), and myocardial endothelin receptor A (ETA) expression (determined by western blotting).

Results:Statistical data showed that the HW/BW ratio was significantly decreased in the drug treatment group. XJEK treatment could improve the heart systolic and diastolic function and ameliorate hemodynamic parameters and vascular remodeling indexes. Colorimetric results showed that, compared with the model group, XJEK increased serum SOD, NOlevels, and decreased those of serum MDA and Ang II. XJEK reverted changes in cardiac pathology, decreased the myocardial cross-sectional area, collagen volume fraction and perivascular collagen area and improved endothelial dysfunction (ED) by promoting eNOS activity, enhancing NO bioavailability, increasing the expression of BH4 and decreasing ETA content. In addition, treatment with XJEK decreased ADMA content in the myocardium.

Conclusion:In conclusion, XJEK mitigates cardiac remodeling in high-salt-induced hypertensive mice. The potential mechanism involves improved oxidative stress and endothelial dysfunction, independently of ameliorating BP.

Le texte complet de cet article est disponible en PDF.

Abbreviations : XJEK, LV, LVH, CR, SBP, LVSP, LVEDP, ±dp/dtmax, RAS, HE, VG, CSA, TAA, AR, MT, ELISA, ED, ET-1, ETA, NO, eNOS, OS, ROS, SOD, MDA, BH4, AngII, ADMA, l-Arg, HW/BW, WB

Keywords : Hypertension, Cardiac remodeling, Endothelial dysfunction, Oxidative stress


Plan


© 2019  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 115

Article 108937- juillet 2019 Retour au numéro
Article précédent Article précédent
  • Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway
  • Qiongyan Lin, Hui Chen, Minfen Zhang, Hanzhen Xiong, Qingping Jiang
| Article suivant Article suivant
  • Apigenin relaxes rat intrarenal arteries, depresses Ca2+-activated Cl? currents and augments voltage-dependent K+ currents of the arterial smooth muscle cells
  • Yixin Jing, Rui Chen, Miaomiao Dong, Yu Liu, Xiaomin Hou, Pengmei Guo, Weiping Li, Jiyuan Lv, Mingsheng Zhang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.